Rima Lahoulou
Puteaux, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
Journal: The Journal of infectious diseases
Published: February 11, 2026
Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1.
Journal: Open forum infectious diseases
Published: November 13, 2025
Doravirine Resistance Patterns Identified through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 23, 2025
Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: October 22, 2025
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
Journal: Lancet (London, England)
Published: August 04, 2025
Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: April 25, 2025
Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen.
Journal: Open forum infectious diseases
Published: April 24, 2025
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.
Journal: Open forum infectious diseases
Published: December 10, 2024
Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 04, 2024
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Journal: The lancet. HIV
Published: February 17, 2023
Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.
Journal: BMC infectious diseases
Published: July 04, 2017
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Journal: Infectious diseases (London, England)
Published: January 14, 2016
Last Updated: 09/26/2026